Market accessOfficial

Denmark changes Cosentyx dispensing group for rheumatological indications from 9 November

🇩🇰 DKMA · Wed 28 Oct 2026

The Danish Medicines Agency is moving secukinumab (Cosentyx) from dispensing group NBS (derma) to NBS (derma, reuma) for its rheumatology uses.

The Danish Medicines Agency (DKMA) announced on 28 October 2026 that Cosentyx, which contains secukinumab, will change dispensing group. The change takes effect on 9 November.

The change applies to the rheumatological indications. The dispensing group moves from NBS (derma) to NBS (derma, reuma), so the classification will cover rheumatology as well as dermatology.

The short notice does not explain the practical consequences, such as who may prescribe the product or how supply is arranged. Companies and healthcare organisations should check DKMA's wider guidance on dispensing groups for details.

In general, a dispensing group is the classification that governs how a medicine may be supplied and under what conditions.

What it means for your team

  • Regulatory affairs teams should check whether Danish product information, labelling or internal databases need updating to the new NBS (derma, reuma) classification before 9 November.
  • Market-access and commercial teams should confirm with DKMA what the change means for prescribing and supply of Cosentyx in rheumatology.
  • PV and QA teams should update their records for the Danish dispensing status, which applies only to the rheumatological indications.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →